Remove Disease Remove Long-Term Care Facilities Remove Virus
article thumbnail

U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna’s COVID-19 Vaccine for Persons 18 Years and Older

The Pharma Data

Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted today to recommend the use of the Moderna COVID-19 vaccine in people 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. .–( BUSINESS WIRE )– Moderna, Inc., AUTHORIZED USE.

Vaccine 52
article thumbnail

Keeping tabs on Covid-19: BioNTech buys GMP-certified facility to boost vaccine…

The Pharma Data

BioNTech plans to manufacture additional therapeutic and vaccine drug candidates at the plant, such as other mRNA vaccines, antibody and cell and gene therapy candidates to support the development of its diversified cancer and infectious disease product pipeline.

Vaccine 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Drop in COVID Cases Seen in Nursing Homes as U.S. Vaccine Effort Makes Headway

The Pharma Data

million shots have now been administered in long-term care facilities, according to the U.S. Centers for Disease Control and Prevention. 1.351 variant contains a key mutation that appears to allow the virus to elude the full power of antibody treatments and vaccines. ” As of Saturday, more than 3.5

Nurses 52
article thumbnail

Bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together

The Pharma Data

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing.

article thumbnail

Lilly Announces Agreement with U.S. government to Supply 300,000 vials of Investigational Neutralizing Antibody Bamlanivimab (LY-CoV555) in an Effort to Fight COVID-19

The Pharma Data

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially preventing and treating COVID-19. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. www.lilly.com?and?www.lilly.com/news.?P-LLY.

article thumbnail

FDA Advisory Panel Says Yes to Pfizer’s COVID Vaccine

The Pharma Data

Centers for Disease Control and Prevention will also vote on whether to recommend the vaccine and for whom, the Post reported. First in line are health care personnel and residents and staff of long-term care facilities, according to earlier recommendations released by the CDC panel.

Vaccine 52
article thumbnail

Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19

The Pharma Data

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. AZD7442 was well tolerated in the trial.

Trials 52